Inflammatory Bowel Diseases, Primary Sclerosing Cholangitis
Conditions
Brief summary
Inflammatory bowel diseases (IBD) include Crohn's disease (CD) and ulcerative colitis (UC). These diseases are a public health problem because they concern many patients (1 case in 1000). IBDs are characterized by dysregulated immune response against luminal antigens causing chronic inflammation of the gut in genetically predisposed individuals. Their exact cause is unknown and there is currently no cure. The primary sclerosing cholangitis (PSC) is a liver inflammatory disease of unknown origin that is known to be strongly associated with IBD. An important clinical observation highlights the mild symptoms of IBD when associated to the PSC. Conversely, treating PSC by liver transplant or immunosuppressive drugs is associated with a progression of intestinal inflammation. Based, on these clinical findings that suggest a protective effect regulator of liver inflammation on intestinal inflammation, and on the results obtained by our group in mouse models that identified the natural killer T cell (NKT) as essential in control of experimental colitis, the project aims to determine, using PCR, if the expression of NKT cell markers are increased in the colon of patients with PSC+IBD compared to patients with IBD alone or PSC alone.
Interventions
OTHERcollection of gut biopsies collection of blood samples
Four to eight colon biopsies will be sampled during endoscopy. Thirty milliliters of blood will be sampled.
Sponsors
University Hospital, Lille
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with PSC alone, IBD alone or PSC + IBD * Obtention of oral and written consent * Patients affiliated with the social security system
Exclusion criteria
* Minor patient * Suspicion of malignant lesion of the colon * Inability for information * person unable to consent, and not benefiting from a legal protection regimen * Person deprived of liberty
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The increase in the expression of the NKT marker Valpha24 mRNA by PCR in the colon of patients with PSC alone, PSC + IBD compared to patients with IBD alone | Through study completion, an average of 1 year |
Secondary
| Measure | Time frame |
|---|---|
| The number of NKT infiltrating colonic biopsies, using immunohistochemical staining | Through study completion, an average of 1 year |
| The percentage of NKT cells among the peripheral blood lymphocytes by flow cytometry | At the time of the inclusion |
Countries
France
Outcome results
None listed